But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Announced Wednesday, the acquisition will hand the Swiss pharmaceutical firm a drug prospect called farabursen, which ...

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Living organ donors take time off work and endure surgery to save the life of someone they may never meet. And we ask them to ...

Real-world data supports tolvaptan use to slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).

Polycystic kidney disease (PKD) is a genetic disorder whereby ... Repurposing ROCK2 is a viable treatment for ciliopathies, for which a limited therapeutic option is available.

Lupin receives USFDA approval for generic Tolvaptan tablets to treat kidney disease, launching soon with 180-day exclusivity.